Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading RLYB daily closes…
Loading price history…
Pipeline assets
RLYB116
Phase 1 · ActiveModality: small molecule
Target C5
Indications
Complement-related diseases(Phase 1)
Status note Lead program; once-weekly, small-volume subcutaneously injected inhibitor of C5 for complement-related diseases. Completed two Phase 1 studies and a confirmatory PK/PD study in healthy volunteers in 2025 (data reported Q1 2026).
RLYB212
Phase 2 · Terminated
Indications
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)(Phase 2)
Status note Program for the prevention of FNAIT discontinued in April 2025 after Phase 2 PK results did not achieve target concentrations, including the minimum target concentration required for efficacy.
RLYB331
Preclinical · ActiveModality: monoclonal antibody
Target MTP-2
Status note Preclinical monoclonal antibody targeting MTP-2. Worldwide exclusive rights obtained in May 2022. Indication not stated in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
926,352
+905,817
0.70%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.